Search…

Lates News

22/09/2025

According to the Financial Times, Pfizer will acquire Metsera at a cash price of $47.50 per share, with an additional payment of $22.50 per share if certain performance targets are met.

Latest

2 m ago

In 2024, the total amount of contracts for the transformation of scientific and technological achievements was 226.91 billion yuan, an increase of about 10% year-on-year.

3 m ago

Sanofi announced on September 22 that the U.S. Food and Drug Administration (FDA) has extended the review date of the new drug application (NDA) for the BTK inhibitor Tolebrutinib by three months. Based on supplementary analysis data submitted during the review period, the FDA deemed the additional information to constitute a significant revision to the NDA, and therefore extended the target action date accordingly. The revised FDA decision target date is now December 28, 2025. Sanofi expressed confidence in the potential positive therapeutic effects of this product.

3 m ago

Sanofi: FDA extends review period for new drug application for Tolebrutinib, a BTK inhibitor.

4 m ago

Hong Kong stock market abnormal movement | Consumer electronics concept stocks see increased gains. OpenAI may be in contact with Guo Lian companies to develop hardware. Reports suggest Apple is requesting an increase in iPhone production on the 17th.

4 m ago

Industry insiders have confirmed that OpenAI has already started collaborating with the domestic supply chain on relevant projects.

+852 - 60190728

Customer Support

Commercial Services